Nyrada Inc. Stock

NYR

AU0000070195

Biotechnology & Medical Research

Market Closed - Australian S.E. 02:10:07 2026-08-24 EDT			5-day change	1st Jan Change
0.7400 ^AUD	-0.67%		+0.68%	-33.93%

08-20	Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%	MT
08-17	Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI

Last Transcript: Nyrada Inc.

Nyrada Inc. - Special Call

02-04

More transcripts

Managers and Directors: Nyrada Inc.

Manager	Title	Age	Since
James Bonnar CEO	Chief Executive Officer	-	2018-01-31
Alexandra Suchowerska CTO	Chief Tech/Sci/R&D Officer	-	-
Benjamin Evison CTO	Chief Tech/Sci/R&D Officer	-	2019-08-23

Director	Title	Age	Since
John Moore CHM	Chairman	61	2019-07-15
Marcus Frampton BRD	Director/Board Member	46	2019-05-31
James Bonnar BRD	Director/Board Member	-	2025-10-07

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NYRADA INC.	-0.67%	+0.68%	+196.00%	+2,640.74%	132M
LONZA GROUP AG	-0.86%	+4.03%	+2.86%	+23.39%	51.61B
REVOLUTION MEDICINES, INC.	-1.18%	-2.35%	+480.35%	+550.57%	44.89B
IQVIA HOLDINGS INC.	+0.07%	+8.35%	+39.03%	+21.29%	42.77B
BEONE MEDICINES AG	-1.88%	+1.23%	+18.90%	+84.51%	42.58B
CELLTRION, INC.	-0.93%	-4.33%	+16.18%	+55.82%	31.82B
MEDPACE HOLDINGS, INC.	-0.37%	+4.24%	+33.34%	+146.19%	17.33B
ASCENDIS PHARMA A/S	-1.24%	+0.46%	-	-	16.63B
EUROFINS SCIENTIFIC SE	+0.36%	+4.43%	+9.53%	+30.58%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.12%	+3.61%	+80.98%	+49.53%	14.09B
Average	-0.67%	+4.63%	+97.46%	+400.29%	27.66B
Weighted average by Cap.	-0.83%	+4.72%	+102.27%	+139.40%

See all sector performances

Nyrada Inc. is an Australia-based biotechnology company. The Company is focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The Companyâ€™s lead candidate, Xolatryp, is a small molecule cardio protection and neuroprotection therapy. Xolatryp has demonstrated preclinical efficacy as an acute treatment following ischemic stroke, traumatic brain injury (TBI), and acute myocardial infarction (AMI). Xolatryp, is also a novel blocker targeting TRPC 3/6/7 ion channels, developed to mitigate secondary brain injury and prevent further brain cell death. The critical role of TRPC 3/6/7 channels in secondary injury has been validated in animal knockout models and through research-grade blockers. Its medical programs include Myocardial Ischemia and Arrhythmia Control, Stroke, and Traumatic Brain Injury.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-24	A$0.7400	-0.67%	136,546
26-08-21	A$0.7450	+0.68%	336,971
26-08-20	A$0.7400	+4.23%	204,367
26-08-19	A$0.7100	-1.39%	139,652
26-08-18	A$0.7200	-2.04%	142,064

Delayed Quote Australian S.E.

More quotes

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	183M 131M 112M 105M 96.16M 180M 12.54B 1.24B 484M 6.3B 492M 481M 20.84B	P/E 2025	-9.91x	P/E 2026	-16.4x
Enterprise Value	174M 125M 107M 100M 91.75M 172M 11.97B 1.18B 462M 6.01B 470M 459M 19.88B	EV / Sales 2025	19.9x	EV / Sales 2026	51.1x
Free-Float	45.65%	Yield 2025 *	-	Yield 2026	-

08-20	Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%	MT
08-17	Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI
07-26	Nyrada Builds Cash Balance in June Quarter With Receipt of R&D Tax Incentive	MT
07-05	Nyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate	MT
06-15	Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion	MT
06-03	Nyrada Completes Cardioprotection Pilot Study for Lead Drug Candidate	MT
05-20	Nyrada Says 7 Million Unlisted Options Due to Expire in June; Shares Fall 3%	MT
05-19	Nyrada Says Rodent Study Shows Drug Candidate's Anti-Tumor Activity, Shares Up 14%	MT
05-19	Nyrada seeks trading halt	RE
04-21	Nyrada Confirms Activation of First Site in Phase 2a Study of Drug Candidate for Heart Muscle Cell Damage	MT
03-18	Nyrada On Track To Being Site Initiation Visits For Phase IIa Clinical Trial	MT
02-18	Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2025	CI
02-18	Nyrada Discloses Updated Capital Structure	MT

22-07-25	Nyrada : Quarterly Activities Report and Appendix 4C	PU
22-06-05	Nyrada : Brain Injury Program Target Unveiled and Phase I Update	PU
22-04-18	Nyrada : Quarterly Activities Report & Appendix 4C	PU
22-03-01	Nyrada : Presentation to Meet the CEO Life Sciences Edition	PU
22-01-20	Nyrada : Quarterly Activities Report & Appendix 4C	PU

1 day	-0.67%
1 week	+0.68%
Current month	+15.62%
1 month	+37.04%
3 months	+37.04%
6 months	+22.31%
Current year	-33.93%

1 week	0.67	0.8
1 month	0.52	0.8
Current year	0.39	1.44
1 year	0.22	1.44
3 years	0.02	1.44
5 years	0.02	1.44
10 years	0.02	1.44

Nyrada Inc. Stock

Stocks

NYR

AU0000070195

Biotechnology & Medical Research

Valuation: Nyrada Inc.

Chart: Nyrada Inc.

Latest news : Nyrada Inc.

Last Transcript: Nyrada Inc.

Press Releases: Nyrada Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Nyrada Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/20/26	Christopher Cox	Free	Director	600,000	0.5485%
2/20/26	Rüdiger Weseloh	Free	Director	600,000	0.5485%
2/20/26	Christopher Cox	Free	Director	600,000	0.5485%

	2025	2026
Net sales	2.4M 1.72M 1.47M 1.38M 1.26M 2.37M 164M 16.27M 6.34M 82.57M 6.45M 6.31M 273M	2.01M 1.44M 1.23M 1.16M 1.06M 1.99M 138M 13.65M 5.32M 69.29M 5.41M 5.3M 229M
Net income	-4.85M -3.47M -2.98M -2.78M -2.55M -4.78M -332M -32.89M -12.83M -167M -13.04M -12.76M -552M	-6.56M -4.7M -4.03M -3.77M -3.45M -6.47M -450M -44.51M -17.36M -226M -17.65M -17.26M -747M
Net Debt	-2.93M -2.1M -1.8M -1.68M -1.54M -2.89M -201M -19.89M -7.76M -101M -7.89M -7.72M -334M	-8.38M -6.01M -5.15M -4.82M -4.41M -8.28M -575M -56.91M -22.19M -289M -22.57M -22.08M -955M